Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Barosi

Showing results (1-10 of 222) with videos related to

Pageof 23
Sort By:
Expert Review of Hematology|July 12, 2012
Emerging targeted therapies in myelofibrosisGiovanni Barosi
Haematologica|October 13, 2022
Idiopathic splanchnic vein thrombosis: is it really idiopathic?Giovanni Barosi
Best Practice & Research. Clinical Haematology|September 6, 2014
Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matterGiovanni Barosi
Current Hematologic Malignancy Reports|August 17, 2015
Setting Appropriate Goals for the Next Generation of Clinical Trials in MyelofibrosisGiovanni Barosi
Hematology/Oncology Clinics of North America|October 17, 2003
Myelofibrosis with myeloid metaplasiaGiovanni Barosi
European Journal of Haematology. Supplementum|August 31, 2007
New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemiaGiovanni Barosi
Current Hematologic Malignancy Reports|August 21, 2014
An immune dysregulation in MPNGiovanni Barosi
Seminars in Hematology|October 8, 2005
Idiopathic myelofibrosisGiovanni Barosi, Ronald Hoffman
Lancet (London, England)|November 16, 2002
Screening for factor V Leiden mutation in pregnant womenMonia Marchetti, Giovanni Barosi
Pharmacoeconomics|November 5, 2004
Clinical and economic impact of epoetins in cancer careMonia Marchetti, Giovanni Barosi
Pageof 23

Showing results (1-10 of 222) with videos related to

Sort By:
Pageof 23
Expert Review of Hematology|July 12, 2012
Emerging targeted therapies in myelofibrosisGiovanni Barosi
Haematologica|October 13, 2022
Idiopathic splanchnic vein thrombosis: is it really idiopathic?Giovanni Barosi
Best Practice & Research. Clinical Haematology|September 6, 2014
Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matterGiovanni Barosi
Current Hematologic Malignancy Reports|August 17, 2015
Setting Appropriate Goals for the Next Generation of Clinical Trials in MyelofibrosisGiovanni Barosi
Hematology/Oncology Clinics of North America|October 17, 2003
Myelofibrosis with myeloid metaplasiaGiovanni Barosi
European Journal of Haematology. Supplementum|August 31, 2007
New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemiaGiovanni Barosi
Current Hematologic Malignancy Reports|August 21, 2014
An immune dysregulation in MPNGiovanni Barosi
Seminars in Hematology|October 8, 2005
Idiopathic myelofibrosisGiovanni Barosi, Ronald Hoffman
Lancet (London, England)|November 16, 2002
Screening for factor V Leiden mutation in pregnant womenMonia Marchetti, Giovanni Barosi
Pharmacoeconomics|November 5, 2004
Clinical and economic impact of epoetins in cancer careMonia Marchetti, Giovanni Barosi
Pageof 23